Moderna creates senior vice president role for global expansion
mRNA specialist Moderna has appointed Chantal Friebertshäuser into the newly created role of Senior Vice President, Commercial, Europe, Middle East and Canada, effective January 1, 2023.
Friebertshäuser will be responsible for commercial efforts in Europe, Middle East and Canada, reporting to Arpa Garay, Moderna's Chief Commercial Officer. Moderna says her experience in leading global teams and scaling commercial organizations regionally will be instrumental as the company enters new markets and advances its portfolio.
Friebertshäuser joins Moderna from Merck Sharp & Dohme (MSD), where she served in a variety of in-market and global commercial leadership roles across 15 years, including her most recent position of Human Health Senior Vice President and Managing Director at MSD Germany. In this role, she was responsible for the company's Human Health Organization and also led the MSD Country Council which convened leaders from the organization's Human Health, Animal Health, Research and Manufacturing sites.
Other prior roles include German Business Unit Leader, Global Market Access Leader, Managing Director of Austria and Global Commercial Lead for the company's HPV vaccine franchise. Prior to MSD, Friebertshäuser spent 10 years in various roles at Eli Lilly.
Friebertshäuser holds a Master of Arts in International Business from the School of Business ESC in Rennes, France. She will be based in Switzerland.